Invention Grant
US09376380B2 Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
有权
大麻素受体2（CB2）反向激动剂和多发性骨髓瘤和骨质疏松症骨病的治疗潜力
- Patent Title: Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
- Patent Title (中): 大麻素受体2（CB2）反向激动剂和多发性骨髓瘤和骨质疏松症骨病的治疗潜力
-
Application No.: US14305941Application Date: 2014-06-16
-
Publication No.: US09376380B2Publication Date: 2016-06-28
- Inventor: Xiang-qun Xie , Peng Yang , Rentian Feng
- Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicant Address: US PA Pittsburgh
- Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Current Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Current Assignee Address: US PA Pittsburgh
- Agency: Foley & Lardner LLP
- Main IPC: C07C233/40
- IPC: C07C233/40 ; C07C311/20 ; C07C311/05 ; C07D211/06 ; C07C311/48 ; C07D235/12 ; C07D203/08 ; C07C69/78 ; C07C233/36 ; C07C311/29 ; C07D295/135 ; C07D213/56 ; C07C311/18 ; C07C233/11 ; C07C233/13 ; C07C233/22 ; C07C233/63 ; C07C233/78
Abstract:
Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
Public/Granted literature
Information query
